Melanoma Clinical Trials in Dallas

Showing 161-180 of 236 trials

A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State

NCT02608034

This is a two-part, Phase 1, open-label, multicenter, two-period, one-sequence study to investigate the effect of itraconazole and rifampin on the PK of vemurafenib following multiple 960 milligrams (mg) twice daily (BID) dosing in adult participants with unresectable Stage IIIC or Stage IV metastatic melanoma positive for the BRAF V600 mutation, or other malignant tumor types that harbor a V600-activating mutation of BRAF where the participant has no acceptable standard treatment options.

Metastatic Melanoma, BRAF V600 Mutation Positive

Genentech, Inc.32 participantsStarted May 2016

Dallas, Texas, United States • Haifa, Israel • Jerusalem, Israel +8 more locations

COMPLETEDPhase 2< 1 mile

Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec

NCT02014441

The primary objective was to estimate the proportion of participants with detectable talimogene laherparepvec deoxyribonucleic acid (DNA) in the blood and urine at any time after administration of talimogene laherparepvec within the first 3 cycles.

Melanoma

Amgen61 participantsStarted Apr 2014

Tampa, Florida, United States • Indianapolis, Indiana, United States • Louisville, Kentucky, United States +11 more locations

A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State

Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec

Melanoma Trials in Other Cities

CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext)

A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )

A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma

A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

X4P-001 and Pembrolizumab in Patients With Advanced Melanoma

Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain

Safety Study of PLX4032 in Patients With Solid Tumors

Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery

A Study of Tasisulam in Treating Participants With Malignant Melanoma

A Study of Vemurafenib in Participants With Metastatic Melanoma

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Other Conditions in Dallas